Brian Rini, MD, on Key Practice Changing Abstracts in Prostate Cancer From 2021 ESMO

Brian Rini, MD, discussed abstracts presented during the 2021 ESMO Congress that will have an immediate impact on prostate cancer.

CancerNetwork® spoke with Brian Rini, MD, chief of clinical trials and professor of medicine at the Vanderbilt-Ingram Cancer Center, about intriguing abstracts presented at the 2021 European Society for Medical Oncology (ESMO) Congress. He mentioned a pair of abstracts in prostate cancer that will impact practice moving forward.


In prostate cancer, there were 2 studies presented that will change practice. One was called PEACE-1 (NCT01957436), which looked at triplet therapy versus doublet therapy in prostate cancer. [The trial compared] 2 different hormonal agents plus chemotherapy versus just 1 hormone agent plus chemotherapy and showed a survival advantage that will absolutely impact practice. And then another in the rising PSA setting, looking at double hormone therapy versus single hormone therapy that also showed great results. I think those will immediately change practice.


Fizazi K, Charles Galceran J, Foulon S, et al. A phase III trial with a 2x2 factorial design in men with de novel metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus prednisone in PEACE-1. J Clin Oncol. 2021;39(no. 15_suppl):5000-5000. doi: 10.1200/JCO.2021.39.15_suppl.5000

Related Videos
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Expert on prostate cancer
Expert on prostate cancer
Experts on prostate cancer
Expert on prostate cancer
A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.
Related Content